PE20230159A1 - Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos - Google Patents
Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usosInfo
- Publication number
- PE20230159A1 PE20230159A1 PE2022001098A PE2022001098A PE20230159A1 PE 20230159 A1 PE20230159 A1 PE 20230159A1 PE 2022001098 A PE2022001098 A PE 2022001098A PE 2022001098 A PE2022001098 A PE 2022001098A PE 20230159 A1 PE20230159 A1 PE 20230159A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- oxoisoindolin
- piperidin
- methoxy
- dione
- Prior art date
Links
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical class O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100020716 Protein Wiz Human genes 0.000 abstract 2
- 101710186935 Protein Wiz Proteins 0.000 abstract 2
- 208000034737 hemoglobinopathy Diseases 0.000 abstract 2
- 208000018337 inherited hemoglobinopathy Diseases 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- UCRSTLCVZRQISL-UHFFFAOYSA-N 3-(6-methoxy-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1C2=CC(OC)=CC=C2C(=O)N1C1CCC(=O)NC1=O UCRSTLCVZRQISL-UHFFFAOYSA-N 0.000 abstract 1
- RHSPRKSLMMGCDU-GEPVFLLWSA-N 3-[6-[[(2R)-1-[(1-cyclohexylpyrazol-4-yl)methyl]piperidin-2-yl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1(CCCCC1)N1N=CC(=C1)CN1[C@H](CCCC1)COC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O RHSPRKSLMMGCDU-GEPVFLLWSA-N 0.000 abstract 1
- 208000019838 Blood disease Diseases 0.000 abstract 1
- 108010044495 Fetal Hemoglobin Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 abstract 1
- 206010043391 Thalassaemia beta Diseases 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invencion se refiere a compuestos derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona de formula (I'); en donde Y es O, CH2, CF2, y CHF; z es de 0 a 2; RX1 y RX2 es cada uno, independientemente, H y alquilo C1-C6; RY1 y RY2 es cada uno, independientemente, H y alquilo C1-C6; RZ1 y RZ2 son ambos hidrogeno; R1 es H y alquilo C1-C6; R2 es H, -C(=O)-R3 , cicloalquilo C3-C8, haloalquilo C1-C6 y alquilo C1-C10. Un compuesto seleccionado es 3-(5-(((R)-1-((1-ciclohexil-1H-pirazol-4-il)metil) piperidin-2-il)metoxi)-1-oxoisoindolin-2- il)piperidin-2,6-diona. Tambien refiere a una composicion farmaceutica que los comprende. Dichos compuestos son efectivos para reducir los niveles de expresion de la proteina Motivos de Dedos de Zinc Ampliamente Interespaciados (WIZ) y/o para inducir la expresion de la hemoglobina fetal (HbF), siendo util en el tratamiento de trastornos sanguineos hereditarios (hemoglobinopatias, beta-hemoglobinopatias), tales como la enfermedad de celulas falciformes y la betatalasemia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950048P | 2019-12-18 | 2019-12-18 | |
| PCT/IB2020/062070 WO2021124172A1 (en) | 2019-12-18 | 2020-12-16 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230159A1 true PE20230159A1 (es) | 2023-02-01 |
Family
ID=73856242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001098A PE20230159A1 (es) | 2019-12-18 | 2020-12-16 | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11566022B2 (es) |
| EP (1) | EP4076650B1 (es) |
| JP (1) | JP7682181B2 (es) |
| KR (1) | KR20220114065A (es) |
| CN (1) | CN114828959B (es) |
| AR (1) | AR120773A1 (es) |
| AU (1) | AU2020410514A1 (es) |
| BR (1) | BR112022011796A2 (es) |
| CA (1) | CA3164832A1 (es) |
| CO (1) | CO2022008243A2 (es) |
| CR (1) | CR20220278A (es) |
| DO (1) | DOP2022000121A (es) |
| EC (1) | ECSP22055267A (es) |
| ES (1) | ES2980575T3 (es) |
| IL (1) | IL293530A (es) |
| JO (1) | JOP20220152A1 (es) |
| MX (1) | MX2022007351A (es) |
| PE (1) | PE20230159A1 (es) |
| PH (1) | PH12022551482A1 (es) |
| TW (1) | TW202130631A (es) |
| UY (1) | UY38986A (es) |
| WO (1) | WO2021124172A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4192825A4 (en) * | 2020-08-07 | 2024-08-28 | Cornell University | CURE PRO MOLECULES THERAPEUTICALLY USEFUL FOR E3 LIGASE-MEDIATED PROTEIN DEGRADATION, AND METHODS OF PREPARATION AND USE THEREOF |
| UY39671A (es) | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
| JP2024520654A (ja) | 2021-06-03 | 2024-05-24 | ノバルティス アーゲー | ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその医療用使用 |
| US20250051347A1 (en) * | 2021-07-30 | 2025-02-13 | Hinova Pharmaceuticals, Inc. | Bifunctional chimeric heterocyclic compound and use thereof as androgen receptor degrader |
| KR20240123836A (ko) * | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| CN118556048A (zh) * | 2022-12-27 | 2024-08-27 | 标新生物医药科技(上海)有限公司 | 基于硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用 |
| CN115959976A (zh) * | 2022-12-30 | 2023-04-14 | 安徽诺全药业有限公司 | 一种甲氧基取代双环戊烷衍生物的制备方法 |
| WO2024255810A1 (en) * | 2023-06-15 | 2024-12-19 | Hangzhou Glubio Pharmaceutical Co., Ltd | Dihydropyrimidine-2, 4 (1h, 3h) -dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| WO2002059300A2 (en) | 2000-12-28 | 2002-08-01 | J & J Research Pty Ltd | Double-stranded rna-mediated gene suppression |
| EP1631260A2 (en) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| ES2956743T3 (es) * | 2010-02-11 | 2023-12-27 | Celgene Corp | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos |
| AU2011329619A1 (en) | 2010-11-18 | 2013-05-02 | Deuteria Pharmaceuticals, Inc. | 3-deutero-pomalidomide |
| WO2012079022A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| WO2014018866A1 (en) | 2012-07-27 | 2014-01-30 | Celgene Corporation | Processes for preparing isoindoline-1,3-dione compounds |
| JP2018523823A (ja) | 2015-08-04 | 2018-08-23 | セルジーン コーポレイション | 慢性リンパ球性白血病の治療方法及び免疫調節療法に対する臨床的感度の予測因子としてのバイオマーカーの利用 |
| CN109071552B (zh) | 2016-04-22 | 2022-06-03 | 达纳－法伯癌症研究所公司 | 细胞周期蛋白依赖性激酶4/6(cdk4/6)通过cdk4/6抑制剂与e3连接酶配体的缀合的降解及使用方法 |
| DK3526202T3 (da) | 2016-10-11 | 2025-03-31 | Arvinas Operations Inc | Forbindelser og fremgangsmåder til målrettet degradering af androgenreceptor |
| IL304982A (en) | 2016-11-01 | 2023-10-01 | Arvinas Operations Inc | Tau-protein targeting protacs and associated methods of use |
| KR102674902B1 (ko) | 2016-12-01 | 2024-06-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
| RU2019121527A (ru) | 2016-12-23 | 2021-01-15 | Эрвинэс Оперейшнс, Инк. | Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES |
| MX2019007649A (es) | 2016-12-23 | 2019-09-10 | Arvinas Operations Inc | Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente. |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| US10604506B2 (en) | 2017-01-26 | 2020-03-31 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| US11999802B2 (en) * | 2017-10-18 | 2024-06-04 | Novartis Ag | Compositions and methods for selective protein degradation |
| US11505560B2 (en) | 2017-10-20 | 2022-11-22 | Dana-Farber Cancer Institute, Inc. | Heterobifunctional compounds with improved specificity |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US11028088B2 (en) | 2018-03-10 | 2021-06-08 | Yale University | Modulators of BTK proteolysis and methods of use |
| JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| KR20210006356A (ko) | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| AU2019251223A1 (en) * | 2018-04-13 | 2020-11-26 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CA3102214A1 (en) | 2018-06-29 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Ligands to cereblon (crbn) |
| WO2020006262A1 (en) | 2018-06-29 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | New crbn modulators |
| CN113166100A (zh) | 2018-06-29 | 2021-07-23 | 达纳-法伯癌症研究所有限公司 | 免疫调节性化合物 |
| WO2020006265A1 (en) | 2018-06-29 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Bispecific degraders |
| US12227488B2 (en) | 2018-12-03 | 2025-02-18 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of Helios and methods of use |
| EP3897637A1 (en) * | 2018-12-20 | 2021-10-27 | Novartis AG | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
-
2020
- 2020-12-16 AU AU2020410514A patent/AU2020410514A1/en not_active Abandoned
- 2020-12-16 BR BR112022011796A patent/BR112022011796A2/pt not_active Application Discontinuation
- 2020-12-16 EP EP20828350.7A patent/EP4076650B1/en active Active
- 2020-12-16 KR KR1020227024287A patent/KR20220114065A/ko active Pending
- 2020-12-16 AR ARP200103501A patent/AR120773A1/es not_active Application Discontinuation
- 2020-12-16 MX MX2022007351A patent/MX2022007351A/es unknown
- 2020-12-16 ES ES20828350T patent/ES2980575T3/es active Active
- 2020-12-16 PH PH1/2022/551482A patent/PH12022551482A1/en unknown
- 2020-12-16 UY UY0001038986A patent/UY38986A/es not_active Application Discontinuation
- 2020-12-16 CN CN202080087049.9A patent/CN114828959B/zh active Active
- 2020-12-16 JP JP2022537250A patent/JP7682181B2/ja active Active
- 2020-12-16 TW TW109144481A patent/TW202130631A/zh unknown
- 2020-12-16 US US17/124,127 patent/US11566022B2/en active Active
- 2020-12-16 CR CR20220278A patent/CR20220278A/es unknown
- 2020-12-16 PE PE2022001098A patent/PE20230159A1/es unknown
- 2020-12-16 JO JOP/2022/0152A patent/JOP20220152A1/ar unknown
- 2020-12-16 WO PCT/IB2020/062070 patent/WO2021124172A1/en not_active Application Discontinuation
- 2020-12-16 IL IL293530A patent/IL293530A/en unknown
- 2020-12-16 CA CA3164832A patent/CA3164832A1/en active Pending
-
2022
- 2022-06-13 CO CONC2022/0008243A patent/CO2022008243A2/es unknown
- 2022-06-14 DO DO2022000121A patent/DOP2022000121A/es unknown
- 2022-07-14 EC ECSENADI202255267A patent/ECSP22055267A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11566022B2 (en) | 2023-01-31 |
| TW202130631A (zh) | 2021-08-16 |
| KR20220114065A (ko) | 2022-08-17 |
| IL293530A (en) | 2022-08-01 |
| EP4076650B1 (en) | 2024-02-28 |
| DOP2022000121A (es) | 2022-08-15 |
| CO2022008243A2 (es) | 2022-07-08 |
| WO2021124172A1 (en) | 2021-06-24 |
| CN114828959A (zh) | 2022-07-29 |
| JP2023506642A (ja) | 2023-02-17 |
| CR20220278A (es) | 2022-07-01 |
| EP4076650A1 (en) | 2022-10-26 |
| AU2020410514A1 (en) | 2022-06-30 |
| UY38986A (es) | 2021-07-30 |
| MX2022007351A (es) | 2022-07-19 |
| US20220402904A1 (en) | 2022-12-22 |
| JP7682181B2 (ja) | 2025-05-23 |
| CA3164832A1 (en) | 2021-06-24 |
| ES2980575T3 (es) | 2024-10-02 |
| ECSP22055267A (es) | 2022-08-31 |
| PH12022551482A1 (en) | 2023-11-29 |
| JOP20220152A1 (ar) | 2023-01-30 |
| CN114828959B (zh) | 2024-04-02 |
| AR120773A1 (es) | 2022-03-16 |
| BR112022011796A2 (pt) | 2022-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230159A1 (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos | |
| BR112022010599A2 (pt) | Formas sólidas de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-amina | |
| RU2014129742A (ru) | Производные бензолсульфонамида в качестве модуляторов rorc | |
| AR104714A1 (es) | Compuestos depsipeptídicos como antihelmínticos | |
| EA023500B1 (ru) | Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты | |
| HRP20180199T1 (hr) | Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1) | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| BR112014015402A2 (pt) | composição sólida de cuidado pessoal, produto de cuidado pessoal e método de tratar cabelo e/ou pele | |
| CY1116168T1 (el) | Συγκρυσταλλοι και αλατα αναστολεων toy ccr3 | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| BR112014024479A8 (pt) | Formulações farmacêuticas compreendendo antagonistas de c-cr3 | |
| PE20151666A1 (es) | Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep | |
| RU2008129641A (ru) | Ингибиторы ccr9 активности | |
| CL2023003561A1 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos médicos | |
| CO2021017435A2 (es) | Analogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida | |
| ECSP23076800A (es) | Derivados de pirazolopiridina y sus usos | |
| CY1110644T1 (el) | 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις | |
| JP2016537396A5 (es) | ||
| MX386586B (es) | Cristal de base libre de derivados benzofurano y método de preparación. | |
| EA201000340A1 (ru) | Аминобензилзамещенные циклические сульфоны, полезные в качестве ингибиторов васе | |
| AR082137A1 (es) | Derivados de bisaril(tio)morfolina como modulares s1p y composiciones farmaceuticas que los contienen | |
| KR880001593A (ko) | 4-(아로일아미노)피페리딘부탄아미드 유도체 | |
| AR071363A1 (es) | Derivados de sulfonamida sustituida y su empleo en medicamentos para el tratamiento de enfermedades mediadas por receptores b1r. | |
| AR109688A1 (es) | Compuestos de indazol para uso en lesiones de tendones y/o ligamentos | |
| RU2018130994A (ru) | Новое соединение бисфосфоновой кислоты |